calendar
11 Mar, 2021
SHANGHAI, China, March. 11, 2021 -- Genor Biopharma announced today that the preclinical progress of the company's leading preclinical drug candidates, GB261, GB262, GB263 and GB264 from its San-Francisco based bi-specific/tri-specific antibody platform, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021. The AACR annual meeting will be held between April 10th and April 15th and between May 17th and 21th online. Abstracts have been published on the AACR website.
1706
calendar
08 Mar, 2021
This announcement is made by JHBP (CY) Holdings Limited (the “Company”, together with itssubsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.
1698
calendar
28 Dec, 2020
SHANGHAI, China, December 28, 2020 - Genor Biopharma Co Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, announced today that multiple IND applications of GB491 (cyclin-dependent kinase 4/6 inhibitor) are under review by NMPA, including indications for 1L/2L hormone receptor positive / human epidermal growth factor receptor 2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.
1687
calendar
04 Nov, 2020
SHANGHAI, China, Nov 4, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, announced that its New Drug Application (NDA) for its infliximab biosimilar GB242 to National Medical Products Administration (NMPA) is under review. Genor submitted NDA on October 27 2020 and NMPA accepted on the NDA on November 3 2020, which again demonstrated strong execution capabilities of Genor team.
1684
calendar
27 Oct, 2020
SHANGHAI, China, Oct. 27, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, announced today that it has submitted New Drug Application (NDA) for its infliximab biosimilar GB242 to National Medical Products Administration (NMPA).
1681